FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Instruc	ction 1(b).			File		nt to Section ction 30(h) o							34		liouis	per res		0.0
Name and Address of Reporting Person* DALE MICHAEL D				2. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ABT]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) 100 ABI	(F BOTT PARI	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/19/2021						;	X Officer (give title below) Other (specify below) SENIOR VICE PRESIDENT				·		
	T PARK II		60064		4. If Amendment, Date of Original Filed (Month/Day/Year)							Line) X Form f Form f					
(City)	(S		(Zip) ole I - Nor	Doriv	otivo C	oouritios		irod	Diar	2004 0	f or	Done	ficial	Owned				
1. Title of Security (Instr. 3) 2. Ti			2. Transa Date			ed Date,	3. Transaction Code (Instr.		4. Securities Acquired (A)			(A) or	or 5. Amount of		6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	((A) or (D)	Price	Transact	Transaction(s) (Instr. 3 and 4)			, ,	
Common	shares with	out par value		02/19	/2021			A		10,403	(1)	A	\$0	\$0 45,166 D				
			Table II -			curities <i>i</i> Ils, warra								Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security			ransactioi ode (Instr		ve (es ed ed nstr.	6. Date Ex Expiration (Month/Da	of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity 4)	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			

Explanation of Responses:

\$124.04

Option

(right to

buy)⁽²⁾

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

Date Exercisable

02/19/2022

2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,775 on February 19, 2022, 17,775 on February 19, 2023, and 17,776 on February 19, 2024.

(D)

(A)

53,326

/s/ Michael D. Dale by Jessica 02/23/2021 H. Paik, Attorney-in-Fact

** Signature of Reporting Person

53,326

\$0

Title

02/18/2031

Common

Shares

Date

53,326

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/19/2021

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.